Home | GSK US
WEBHome | GSK US. Vaccines. People 50 and older are at increased risk for shingles – Protect your power. THRIVE@50+ empowers adults 50 years and older to learn about their risk for shingles.
Home | GSK
WEBWe are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
GSK plc - Wikipedia
WEBGSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with global headquarters in London.
Company | GSK US
WEBExplore GSK in the US. Learn about our US businesses. Oncology. Leading the way to reimagine improved ways of engaging with people with cancer. Respiratory. Helping patients breathe better by redefining treatment for COPD and asthma. Specialty. Transforming immuno-inflammatory clinical practice …
Products | GSK US
WEBProducts. Learn more about our product portfolio and how we're prioritizing vaccines and specialty medicines to get ahead of disease together. Below you can find the full A-Z list of our products available in the United States. Filter by product area. All product areas. Vaccines. Specialty medicines. General medicines.
Company | GSK
WEBWe are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve …
WEBJul 2, 2012 · Global health care giant GlaxoSmithKline LLC (GSK) agreed to plead guilty and to pay $3 billion to resolve its criminal and civil liability arising from the company’s unlawful promotion of certain prescription drugs, its failure to report certain safety data, and its civil liability for alleged false price reporting practices, the Justice ...
GSKForYou | GSK Patient Assistance Program
WEBLearn how our program can assist you if you need help paying for your GlaxoSmithKline prescription medicines and vaccines, whether you have coverage or not.
GSK and CureVac to develop next generation mRNA COVID-19 …
WEBFeb 3, 2021 · GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq: CVAC) today announced a new €150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine.
Sanofi/GSK COVID-19 Vaccine: What You Should Know
WEBJun 1, 2021 · Sanofi Pasteur and GlaxoSmithKline were expecting to start a Phase 3 clinical trial for a vaccine to fight the novel coronavirus (COVID-19) in December 2020. Instead, the Phase 3 trial launched in May 2021 after the pharmaceutical companies went back to the lab to rework the formula and conducted a redo of …
Skip to content